The group's principal activity is to develop and commercialize recombinant human enzymes for the infertility, ophthalmology and oncology markets. The group's business is in the development stage. Its portfolio of products in development stage is based on intellectual property covering the family of human enzymes known as hyaluronidases. The group's first hyaluronidase enzyme, recombinant human pH20 or rhuph20, is the platform for three different products, including a medical device, a drug enhancement agent and a therapeutic biologic.
